New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L01 ANTINEOPLASTIC AGENTS
Combination products are classified in L01XY - Combinations of antineoplastic agents, except for combinations of monoclonal antibodies or antibody drug conjugates which are classified in L01FY.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).
Radiopharmaceuticals used in the treatment of cancer are classified in V10X.
| DDDs have been established for the protein kinase inhibitors in L01E only. No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X. This is because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy. The consumption of antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents. |
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CA Vinca alkaloids and analogues
Synthetic analogues are also classified in this group.
L01CB Podophyllotoxin derivatives
Antivirals for topical use, e.g. podophyllotoxin, see D06BB - Antivirals.
L01CC Colchicine derivatives
Colchicine is classified in M04AC01.
L01CD Taxanes
L01CD01 - paclitaxel includes solvent based paclitaxel and paclitaxel albumin.
L01CE Topoisomerase 1 (TOP1) inhibitors
All formulations of irinotecan (e.g. liposomal) are classified in L01CE02.
L01CX Other plant alkaloids and natural products
Last updated: 2024-01-26